Efficacy should drive atypical antipsychotic treatment

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7383.283/a (Published 01 February 2003) Cite this as: BMJ 2003;326:283
  1. Leslie L Citrome (citrome@nki.rfmh.org), clinical professor of psychiatry
  1. Nathan S Kline Institute for Psychiatric Research, 140 Old Orangeburg Road, Orangeburg, NY 10962, USA

    EDITOR—Koro et al say that olanzapine is associated with a clinically important and significant increased risk of diabetes.1 To date five other pharmacoepidemiological papers have been published about the possible increase in risk for diabetes in patients receiving atypical antipsychotics.26

    All use a variety of methods and have come up with a variety of …

    View Full Text

    Log in

    Log in through your institution


    * For online subscription